| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.19 | 0.0001 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.19 | 0.0002 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.18 | 0.0004 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.18 | 0.0004 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0005 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0007 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0007 |